RenovaCare today touted a win in a patent spat with Avita Medical (ASX:AVH) after the US Patent Office dismissed a challenge to RenovaCare’s patents and denied a trial that Avita was seeking.
RenovaCare said that the USPTO specifically noted that Avita’s arguments “were based on old claims and technologies which had already been considered and rejected,” according to a press release.
“I’m proud of the cutting-edge technologies developed by our team for the millions that suffer from burns and wounds and deserve access to the very latest in medical innovation. Just as we’ve done with this challenge, we’ll aggressively protect our intellectual property while continuing to expand our patent portfolio and enhance shareholder value,” RenovaCare prez & CEO Thomas Bold said in a press release.
The case relates back to an Inter Partes review petition filed by Avita Medical last May against RenovaCare patent No. 9,610,430.
RenovaCare is developing the SkinGun and CellMist system, designed to use a sample of stem cells collected from a patient’s healthy skin. The cells are isolated and placed into a water-based solution in a syringe, which is then attached to the device and sprayed over the wounded area.
The technique allows for a ‘cell mist’, with 10,000s of small regenerated cell colonies which grow outward and connect to each other to create an epithelial skin layer.
Earlier this month, RenovaCare issued a response to shortseller Streetsweeper after the group released a scathing review of the company that was skeptical of its ability to hold its market valuation.
